Short answer
CODEXIS, INC. (CDXS) filed its Q2 2026 10-Q quarterly report on Aug 11, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $15M (down 2.7% year over year) with net income of −$12M.
Q2 2026 key financials · XBRL
- Revenue
- $15M
- −2.7% YoY · −2.2% QoQ
- Net income
- −$12M
- +9.5% YoY · −37.9% QoQ
- Operating margin
- -75.3%
- EPS (diluted)
- −$0.13
- +13.3% YoY · −30.0% QoQ
Source: XBRL data from the CODEXIS, INC. (CDXS) Q2 2026 10-Q on SEC EDGAR. USD.
CODEXIS, INC. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $14.9M, down 3% YoY, with product revenue $13.2M, up 79%, offset by R&D revenue $1.7M, down 79%
- Product gross margin 73% vs 72% YoY, driven by sales mix toward more profitable products
- Best performer: clinical-stage and process-development enzyme sales up $4.1M; commercial-pharma enzyme sales up $1.7M
- Cash and equivalents $27.2M vs $50.8M at December 31, 2025; short-term investments $27.7M vs $27.4M
- Near-term outlook: facility retrofit construction expected in second half of 2026; capital may be needed if plans or assumptions change
Risk Factors
- No newly added risk factor identified; filing carries forward existing risks without quarter-specific additions
- Continued losses: $20.7 million net loss for six months ended June 30, 2026, with accumulated deficit of $627.5 million
- Regulatory classification: FDA could reject FDCA exemption, requiring cGMP compliance and potentially stopping product distribution
- Manufacturing dependence: three locations produce substantially all enzymes, including CMOs in Austria and Italy
- Customer concentration: customers contributing at least 10% represented 60% of six-month 2026 revenue, versus 43% in 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other CODEXIS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.